A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

Inclusion criteria

• 1. Male or female participants, 18-75 years of age.
• 2. Confirmed as T2DM for at least 12 weeks.
• 3. Body Mass Index (BMI): 22 kg/m^2 ≤ BMI ≤ 40 kg/m^2.
• 4. Treated with lifestyle intervention and stable treatment with metformin at least 8 weeks prior to screening.
• 5. HbA1c 7.5-10.5% (both inclusive) at screening visit.
• 6. Able to understand the protocol, and voluntarily signed informed consent.

Exclusion criteria

• 1. Type 1 diabetes or other specific types of diabetes.
• 2. Allergy to any active ingredient or any excipient of the investigational product, or presence of severe allergic diseases at screening.
• 3. Weight change >5% within 1 month before screening.
• 4. History of a level 3 hypoglycemic episode within 6 months prior to screening.
• 5. Acute complications of diabetes occurred within 6 months prior to screening.
• 6. History of severe chronic diabetic complications within 6 months prior to screening, or have non-proliferative diabetic retinopathy that requires treatment during the study.
• 7. History of acute or chronic pancreatitis.
• 8. History of acute cardiovascular and cerebrovascular within 6 months prior to screening.
• 9. History of malignancy of any organ system within 5 years prior to screening, excluding cured basal cell carcinoma and carcinoma in situ.
• 10. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2).
• 11. History of major surgery or suffered blood loss of more than 400 mL within 3 months prior to screening.
• 12. Pregnant or lactating woman.
• 13. Other conditions judged by the investigator to be unsuitable for participation in this trial.